ClinicalTrials.gg
CompletedNCT00866359Updated Jun 19, 2020Results posted

A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease

A Phase 2 interventional study of Apremilast (CC-10004) and Placebo in Behcet Syndrome, sponsored by Amgen. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-19.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Behcet Syndrome with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Behcet Syndrome · United States.

Enrollment
5th of 13
111 · median 60
Started
2009
with 1 other
Phase 2
5 of 26
1 open now
Registered
4th of 26
by date
Lead sponsor
2 of 26
Amgen

Among the 26 studies in Behcet Syndrome with a site in United States, this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2009, is one of 5 in phase 2, and was the 4th registered.

Behcet Syndrome

136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.

Browse Behcet Syndrome studies →

Open to participants now

6 of the 26 studies in Behcet Syndrome with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Behcet Syndrome studies recruiting now, 7 (25%) set no upper age limit and 15 (54%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Behcet Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess whether Apremilast is safe and effective in the treatment of patients with Behcet Disease.

03

Conditions studied

  • Behcet Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Behçet Disease. At the time of diagnosis, subjects must meet the international study group criteria for Behçet Disease
  • Females of (FCBP) must have negative pregnancy tests and agree to use two forms of throughout the study.
  • Males must use barrier contraception (latex condoms) when engaging in reproductive sexual activity with FCBP
  • Laboratory criteria: ≥ 9 g/dL, WBC count ≥ 3000 /microL and ≤14,000/microL, count ≥ 100,000 /microL,, serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L), total ≤ 2.0 mg/dL, and ALT ≤ 1.5 X
  • Two or more oral ulcers over the 28 day period before screening, with or without current treatment
  • Two or more oral ulcers at the time of randomization (Visit 2, Baseline)

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast feeding
  • Any condition which places the subject at risk
  • Systemic fungal infection
  • History of TB infection within 3 years
  • History of recurrent bacterial infection
  • Mycobacterium TB as indicated by a positive PPD skin test
  • History of incompletely treated Mycobacterium tuberculosis
  • chest x-ray abnormality at screening.
  • Clinically significant abnormality at screening
  • History of infection
  • History of congenital or acquired immunodeficiency
  • surface antigen positive or Hepatitis B core antibody positive at screening
  • Antibodies to at screening
  • History of (except for treated basal-cell skin carcinomas > 3 years prior to screening)
  • Any active major organ involvement of Behçet Disease
  • Use of concomitant immune modulating therapy or topical .
  • Use of ocular corticosteroids
  • Use of any medication within 4 weeks prior to randomization or 5 PK/PD half-lives (whichever is longer)
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
111 participants (actual)

Study arms

  • Active comparator
    A. Apremilast

    Drug: Apremilast (CC-10004)

  • Placebo comparator
    B. Placebo Comparator

    Drug: Placebo

Interventions

  • Treatment Phase Days 1-7: Titration from 10 mg BID apremilast tablets arm A (or matching placebo arm B) to 30 mg BID apremilast arm A(or matching placebo arm B) Day 8-84: Maintenance of 30 mg BID apremilast arm A (or matching placebo arm B) Dose reductions to 20 mg BID apremilast arm A (or matching placebo arm B) are permitted. Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast. Day 92-169: Maintenance of 30 mg BID apremilast arm A or dose reductions to 20 mg BID apremilast arm A (if not previously down titrated)

  • DrugPlacebo

    Treatment Phase Days 1-7: Titration from 10mg BID matching placebo (arm B) to 30mg BID placebo (arm B) Day 8-84: Maintenance of 30mg BID placebo (arm B). Dose reductions to 20 mg BID matching placebo (arm B) are permitted. Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast. Day 92-169: Maintenance of 30 mg BID apremilast or dose reductions to 20 mg BID apremilast (if not previously down titrated)

06

What researchers measure

Primary outcomes

  1. Number of Oral Ulcers at Day 85

    The number of oral ulcers were counted at each visit and at the end of the treatment period (starting point was at baseline).

    Time frame: Day 85

Secondary outcomes

  1. Pain of Oral Ulcers as Measured by Visual Analog Scale (VAS) at Day 85

    A 100-mm VAS pain scale for oral ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.

    Time frame: Day 85

  2. Pain of Genital Ulcers as Measured by Visual Analog Scale (VAS) Scores at Day 85

    A 100-mm VAS pain scale for genital ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.

    Time frame: Baseline to Day 85

  3. Area Under the Curve (AUC) for the Number of Oral Ulcers From Day 1 to 85

    Area under curve (AUC\^85) from Day 1 to Day 85 for the number of oral ulcers per day was determined using the trapezoidal rule and divided by the days between the date of the last observation and baseline. The AUC was determined using the LOCF approach to impute missing values.

    Time frame: Day 1 to Day 85

  4. Area Under the Curve for the Number of Genital Ulcers From Day 1 to 85

    Area under curve (AUC\^85) from Day 1 to Day 85 for the number of genital ulcers per day was not analyzed.

    Time frame: Day 1 to Day 85

  5. Area Under the Curve (AUC) for the Number of Oral Plus Genital Ulcers From Day 1 to 85

    Area under curve (AUC) from Day 1 to Day 85 (AUC\^85) for the number of oral plus genital ulcers per day was determined using the trapezoidal rule and divided by the days between the date of the last observation and baseline. The AUC was determined using the LOCF approach to impute missing values.

    Time frame: Day 1 to Day 85

  6. Sum of the Number Oral Ulcers, Genital Ulcers or Oral Plus Genital Ulcers at Day 85

    Sum of the number oral ulcers, genital ulcers or oral plus genital ulcers at Day 85

    Time frame: Day 85

  7. Percentage of Participants Who Were Oral Ulcer-free (Complete Response), or Whose Oral Ulcers Were Reduced by ≥ 50%, (Partial Response)

    Comparison of the percentage of participants who were oral ulcer-free (complete response: free from active oral ulcers), or whose oral ulcers were reduced by ≥ 50%, (partial response) between the apremilast-treated and the placebo-treated groups. In this case, partial response also includes complete response.

    Time frame: Baseline and Day 85

  8. Change From Baseline in the Disease Activity as Measured by BD Current Activity Form/Index Score on Day 85

    The Behçet's Disease Current Activity Index consists of three component scores, a participant's perception of disease activity, a clinician's overall perception of disease activity and a Behçet's Disease Current Activity Index Score. The score ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening) and a negative change from baseline indicates improvement.

    Time frame: Day 1 to Day 85 or to early termination visit

  9. Number of Treatment Emergent Adverse Events (TEAE) During the Placebo Controlled Treatment Phase

    A Treatment Emergent Adverse Event (TEAE) was defined as any AE occurring or worsening on or after the first treatment of any study drug, and within 28 days after the last dose of the last study drug. A treatment related toxicity was considered by the investigator to be not suspected or suspected. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE.

    Time frame: Day 1 to Day 85; maximum exposure to study drug was 13 weeks during treatment phase

  10. Number of New Manifestations of Behçet's Disease or Flare During the Placebo Controlled Treatment Phase

    A flare was defined as the development of new manifestations of BD or worsening of existing disease, meeting the following criteria: 1. Organ involvement: any major organ involvement (eg, central nervous system, gastrointestinal tract); 2. Oral/genital ulcers: ≥ 100% increase in the number of oral or genital ulcers from Day 1 or a minimum increase of 3 in the number of oral or genital ulcers, whichever is greater; 3. Arthritis: ≥ 50% increase in the number of swollen joints, or a minimum increase of 3 swollen joints, whichever is greater; 4. Skin lesions (non-oral/genital ulcers): ≥ 50% increase in the total score of the Physician's Global Assessment of Skin Lesions, or a minimum increase of 2 in the total score of the Physician's Global Assessment of Skin Lesions, whichever is greater' 5. New onset or worsening of existing Behçet Disease-related inflammatory eye disease requiring initiation of immunosuppressive therapy (uveitis).

    Time frame: Day 1 to Day 85

  11. Number of Oral Ulcers at Day 169

    The number of oral ulcers were counted at Day 169 in reference to the participants' first day of active treatment (Day 1 or Day 85).

    Time frame: Day 169

  12. Pain of Oral Ulcers as Measured by VAS (VAS Score) at Day 169

    A 100-mm VAS pain scale for oral ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.

    Time frame: Day 169

  13. Pain of Genital Ulcers as Measured by Visual Analog Scale (VAS) at Day 169

    A 100-mm VAS pain scale for genital ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.

    Time frame: Day 1 to Day 169

  14. Behçet's Disease (BD) Current Activity Index Form Score at Day 169

    The Behçet's Disease Current Activity Index consists of three component scores, a participant's perception of disease activity, a clinician's overall perception of disease activity and a Behçet's Disease Current Activity Index Score. The score ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening) and a negative change from baseline indicates improvement.

    Time frame: Day 169

  15. Number of New Manifestations of Behçet's Disease or Flare That Were Not Present at Day 1

    A flare was defined as the development of new manifestations of BD or worsening of existing disease, meeting the following criteria: 1. Organ involvement: any major organ involvement (eg, central nervous system, gastrointestinal tract); 2. Oral/genital ulcers: ≥ 100% increase in the number of oral or genital ulcers from Day 1 or a minimum increase of 3 in the number of oral or genital ulcers, whichever is greater; 3. Arthritis: ≥ 50% increase in the number of swollen joints, or a minimum increase of 3 swollen joints, whichever is greater; 4. Skin lesions (non-oral/genital ulcers): ≥ 50% increase in the total score of the Physician's Global Assessment of Skin Lesions, or a minimum increase of 2 in the total score of the Physician's Global Assessment of Skin Lesions, whichever is greater; 5. New onset or worsening of existing Behçet Disease-related inflammatory eye disease requiring initiation of immunosuppressive therapy (uveitis).

    Time frame: Day 1 to Day 169

  16. Number of Oral Ulcers at Day 197

    The number of oral ulcers were counted at each visit and at the end of the treatment period (starting point was at baseline).

    Time frame: Day 197

  17. Pain of Oral Ulcers as Measured by VAS (VAS Score) at Day 197

    A 100-mm VAS pain scale for oral ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.

    Time frame: Day 197

  18. Pain of Genital Ulcers as Measured by Visual Analog Scale (VAS) at Day 197

    A 100-mm VAS pain scale for genital ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.

    Time frame: Day 1 to Day 197

  19. Change From Baseline in the Disease Activity as Measured by BD Current Activity Form/Index Score on Day 197

    The Behçet's Disease Current Activity Index consists of three component scores, a participant's perception of disease activity, a clinician's overall perception of disease activity and a Behçet's Disease Current Activity Index Score. The score ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening) and a negative change from baseline indicates improvement.

    Time frame: Day 1 to Day 197

  20. Summary of Treatment Emergent Adverse Events During the Active Treatment-Extension Phase

    A Treatment Emergent Adverse Event (TEAE) is as any AE occurring or worsening on or after the first treatment of any study drug, and within 28 days after the last dose of the last study drug. A treatment related toxicity was considered by the investigator to be not suspected or suspected. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE.

    Time frame: Day 1 to Day 197; maximum exposure was 25.1 weeks

Other outcomes

  1. Percentage of Participants Who Were Genital Ulcer-free (Complete Response) at Day 85

    The percentage of participants who were genital ulcer-free (complete response: free from active genital ulcers)

    Time frame: Baseline to Day 85

  2. Percentage of Participants Who Were Genital Ulcer-free (Complete Response) at Day 169

    The percentage of participants who were genital ulcer-free (complete response: free from active genital ulcers)

    Time frame: Day 1 to Day 169

  3. Percentage of Participants Who Were Genital Ulcer-free (Complete Response)

    The percentage of participants who were genital ulcer-free (complete response: free from active genital ulcers)

    Time frame: Day 1 to Day 197

07

Results

Posted Aug 27, 2014
Limitations and caveats
Planned sample size not reached; slow enrollment

Participant flow

The study was conducted at 3 study sites in Turkey and 3 sites in the United States. The first participant enrolled was enrolled on October 23, 2009 and the last participant enrolled was enrolled on May 08, 2012.

Treatment Phase (Days 1 to 85)
Participant flow — Treatment Phase (Days 1 to 85)
MilestonePlacebo (Oral) BIDApremilast 30mg (Oral) BIDPlacebo/Apremilast 30 mgApremilast 30mg/Apremilast 30mg
Started565500
Completed455000
Not completed11500
Withdrew: Adverse event5400
Withdrew: Lack of efficacy3000
Withdrew: Withdrawal by subject1000
Withdrew: Protocol violation1100
Withdrew: Other1000
Extension Phase (Day 86 to 169)
Participant flow — Extension Phase (Day 86 to 169)
MilestonePlacebo (Oral) BIDApremilast 30mg (Oral) BIDPlacebo/Apremilast 30 mgApremilast 30mg/Apremilast 30mg
Started004550
Completed004447
Not completed0013
Withdrew: Adverse event0013
Observational Follow-Up Phase
Participant flow — Observational Follow-Up Phase
MilestonePlacebo (Oral) BIDApremilast 30mg (Oral) BIDPlacebo/Apremilast 30 mgApremilast 30mg/Apremilast 30mg
Started005454
Completed005454
Not completed0000

Outcome measures

PrimaryNumber of Oral Ulcers at Day 85

The number of oral ulcers were counted at each visit and at the end of the treatment period (starting point was at baseline).

Time frame:
Day 85
Reported as:
Least squares mean · ulcers/participants
Number of Oral Ulcers at Day 85
ulcers/participantsPlacebo (Oral) BIDApremilast 30mg (Oral) BID
Number of Oral Ulcers at Day 852.0 ± 0.280.4 ± 0.28
Statistical analysis
  • Placebo (Oral) BID vs Apremilast 30mg (Oral) BID · ANCOVA · p = <0.0001 · Least squares mean difference: -1.6 · 95% CI -2.4 to -0.9Based on an analysis of covariance model for the number of ulcers at Day 85, with treatment group and gender as factors and the baseline ulcer number as a covariate.
SecondaryPain of Oral Ulcers as Measured by Visual Analog Scale (VAS) at Day 85

A 100-mm VAS pain scale for oral ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.

Time frame:
Day 85
Reported as:
Least squares mean · units on a scale
Pain of Oral Ulcers as Measured by Visual Analog Scale (VAS) at Day 85
units on a scalePlacebo (Oral) BIDApremilast 30mg (Oral) BID
Pain of Oral Ulcers as Measured by Visual Analog Scale (VAS) at Day 8536.7 ± 3.239.9 ± 3.30
Statistical analysis
  • Placebo (Oral) BID vs Apremilast 30mg (Oral) BID · ANCOVA · p = <0.0001 · Least squares mean difference: -26.8 · 95% CI -35.5 to -18.0Based on an analysis of covariance model for the oral ulcer pain VAS at Day 85, with treatment group and gender as factors and the baseline oral ulcer pain VAS as a covariate.
Other pre-specifiedPercentage of Participants Who Were Genital Ulcer-free (Complete Response) at Day 85

The percentage of participants who were genital ulcer-free (complete response: free from active genital ulcers)

Time frame:
Baseline to Day 85
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Genital Ulcer-free (Complete Response) at Day 85
percentage of participantsPlacebo (Oral) BIDApremilast 30mg (Oral) BID
Percentage of Participants Who Were Genital Ulcer-free (Complete Response) at Day 8550100
SecondaryPain of Genital Ulcers as Measured by Visual Analog Scale (VAS) Scores at Day 85

A 100-mm VAS pain scale for genital ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.

Time frame:
Baseline to Day 85

No measurements were reported for this outcome.

SecondaryArea Under the Curve (AUC) for the Number of Oral Ulcers From Day 1 to 85

Area under curve (AUC\^85) from Day 1 to Day 85 for the number of oral ulcers per day was determined using the trapezoidal rule and divided by the days between the date of the last observation and baseline. The AUC was determined using the LOCF approach to impute missing values.

Time frame:
Day 1 to Day 85
Reported as:
Least squares mean · total AUC (#ulcers*days)
Area Under the Curve (AUC) for the Number of Oral Ulcers From Day 1 to 85
total AUC (#ulcers*days)Placebo (Oral) BIDApremilast 30mg (Oral) BID
Area Under the Curve (AUC) for the Number of Oral Ulcers From Day 1 to 85157.82 ± 12.89067.74 ± 13.267
Statistical analysis
  • Placebo (Oral) BID vs Apremilast 30mg (Oral) BID · ANCOVA · p = <0.0001 (The last post-baseline observation was carried forward to Day 85 for participants who discontinued the study before Day 85. For participants who did not have Day 85 visit on the targeted date, the total AUC was adjusted by the actual study days.) · Mean difference (final values): -90.07 · 95% CI -125.32 to -54.82Based on an analysis of covariance model for the number of ulcers at Day 85, with treatment group, gender, and interaction of treatment group and gender as factors and the baseline ulcer number as a covariate.
SecondaryArea Under the Curve for the Number of Genital Ulcers From Day 1 to 85

Area under curve (AUC\^85) from Day 1 to Day 85 for the number of genital ulcers per day was not analyzed.

Time frame:
Day 1 to Day 85

No measurements were reported for this outcome.

SecondaryArea Under the Curve (AUC) for the Number of Oral Plus Genital Ulcers From Day 1 to 85

Area under curve (AUC) from Day 1 to Day 85 (AUC\^85) for the number of oral plus genital ulcers per day was determined using the trapezoidal rule and divided by the days between the date of the last observation and baseline. The AUC was determined using the LOCF approach to impute missing values.

Time frame:
Day 1 to Day 85
Reported as:
Mean · total AUC (#ulcers*days)
Area Under the Curve (AUC) for the Number of Oral Plus Genital Ulcers From Day 1 to 85
total AUC (#ulcers*days)Placebo (Oral) BIDApremilast 30mg (Oral) BID
Area Under the Curve (AUC) for the Number of Oral Plus Genital Ulcers From Day 1 to 85193.95 ± 161.49265.79 ± 108.037
SecondarySum of the Number Oral Ulcers, Genital Ulcers or Oral Plus Genital Ulcers at Day 85

Sum of the number oral ulcers, genital ulcers or oral plus genital ulcers at Day 85

Time frame:
Day 85
Reported as:
Least squares mean · Ulcers/participants
Sum of the Number Oral Ulcers, Genital Ulcers or Oral Plus Genital Ulcers at Day 85
Ulcers/participantsPlacebo (Oral) BIDApremilast 30mg (Oral) BID
Sum of the Number Oral Ulcers, Genital Ulcers or Oral Plus Genital Ulcers at Day 852.3 ± 0.350.6 ± 0.36
Statistical analysis
  • Placebo (Oral) BID vs Apremilast 30mg (Oral) BID · ANCOVA · p = 0.0007 · Mean difference (final values): -1.7 · 95% CI -2.7 to -0.8Based on an analysis of covariance model for the number of ulcers at Day 85, with treatment group, gender, and interaction of treatment group and gender as factors and the baseline ulcer number as a covariate.
SecondaryPercentage of Participants Who Were Oral Ulcer-free (Complete Response), or Whose Oral Ulcers Were Reduced by ≥ 50%, (Partial Response)

Comparison of the percentage of participants who were oral ulcer-free (complete response: free from active oral ulcers), or whose oral ulcers were reduced by ≥ 50%, (partial response) between the apremilast-treated and the placebo-treated groups. In this case, partial response also includes complete response.

Time frame:
Baseline and Day 85
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Oral Ulcer-free (Complete Response), or Whose Oral Ulcers Were Reduced by ≥ 50%, (Partial Response)
percentage of participantsPlacebo (Oral) BIDApremilast 30mg (Oral) BID
Complete Response28.670.9
Partial Response50.089.1
Statistical analysis
  • Placebo (Oral) BID vs Apremilast 30mg (Oral) BID · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted difference (percentage): 39.1 · 95% CI 23.6 to 54.5Adjusted difference in proportions = weighted average of treatment differences across gender with the CMH weights.
SecondaryChange From Baseline in the Disease Activity as Measured by BD Current Activity Form/Index Score on Day 85

The Behçet's Disease Current Activity Index consists of three component scores, a participant's perception of disease activity, a clinician's overall perception of disease activity and a Behçet's Disease Current Activity Index Score. The score ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening) and a negative change from baseline indicates improvement.

Time frame:
Day 1 to Day 85 or to early termination visit
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Disease Activity as Measured by BD Current Activity Form/Index Score on Day 85
units on a scalePlaceboApremilast 30mg (Oral) BID
Change From Baseline in the Disease Activity as Measured by BD Current Activity Form/Index Score on Day 85-0.1 ± 0.22-1.2 ± 0.22
Statistical analysis
  • Placebo vs Apremilast 30mg (Oral) BID · ANCOVA · p = 0.0007 · Mean difference (final values): -1.1 · 95% CI -1.7 to -0.5Based on an Ancova model for change from baseline with treatment group, gender and interaction of treatment group and gender as factors and the baseline value as a covariate.
SecondaryNumber of Treatment Emergent Adverse Events (TEAE) During the Placebo Controlled Treatment Phase

A Treatment Emergent Adverse Event (TEAE) was defined as any AE occurring or worsening on or after the first treatment of any study drug, and within 28 days after the last dose of the last study drug. A treatment related toxicity was considered by the investigator to be not suspected or suspected. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE.

Time frame:
Day 1 to Day 85; maximum exposure to study drug was 13 weeks during treatment phase
Reported as:
Number · participants
Number of Treatment Emergent Adverse Events (TEAE) During the Placebo Controlled Treatment Phase
participantsPlacebo (Oral) BIDApremilast 30mg (Oral) BID
Any TEAE5049
Any drug related TEAE2430
Any severe TEAE55
Any serious TEAE32
Any serious drug related TEAE10
Any TEAE leading to drug interruption01
Any TEAE leading to drug withdrawal54
SecondaryNumber of New Manifestations of Behçet's Disease or Flare During the Placebo Controlled Treatment Phase

A flare was defined as the development of new manifestations of BD or worsening of existing disease, meeting the following criteria: 1. Organ involvement: any major organ involvement (eg, central nervous system, gastrointestinal tract); 2. Oral/genital ulcers: ≥ 100% increase in the number of oral or genital ulcers from Day 1 or a minimum increase of 3 in the number of oral or genital ulcers, whichever is greater; 3. Arthritis: ≥ 50% increase in the number of swollen joints, or a minimum increase of 3 swollen joints, whichever is greater; 4. Skin lesions (non-oral/genital ulcers): ≥ 50% increase in the total score of the Physician's Global Assessment of Skin Lesions, or a minimum increase of 2 in the total score of the Physician's Global Assessment of Skin Lesions, whichever is greater' 5. New onset or worsening of existing Behçet Disease-related inflammatory eye disease requiring initiation of immunosuppressive therapy (uveitis).

Time frame:
Day 1 to Day 85
Reported as:
Number · participants
Number of New Manifestations of Behçet's Disease or Flare During the Placebo Controlled Treatment Phase
participantsPlacebo (Oral) BIDApremilast 30mg (Oral) BID
Participants who had disease flare2712
Participants with new onset or worsening uveitis30
SecondaryNumber of Oral Ulcers at Day 169

The number of oral ulcers were counted at Day 169 in reference to the participants' first day of active treatment (Day 1 or Day 85).

Time frame:
Day 169
Reported as:
Mean · ulcers/participant
Number of Oral Ulcers at Day 169
ulcers/participantPlacebo/Apremilast 30 mgApremilast 30 mg /Apremilast 30mg BID (Oral)
Number of Oral Ulcers at Day 1690.4 ± 1.310.6 ± 1.27
SecondaryPain of Oral Ulcers as Measured by VAS (VAS Score) at Day 169

A 100-mm VAS pain scale for oral ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.

Time frame:
Day 169
Reported as:
Mean · units on a scale
Pain of Oral Ulcers as Measured by VAS (VAS Score) at Day 169
units on a scalePlacebo/Apremilast 30 mgApremilast 30 mg /Apremilast 30mg BID (Oral)
Pain of Oral Ulcers as Measured by VAS (VAS Score) at Day 1699.6 ± 21.139.7 ± 20.33
Other pre-specifiedPercentage of Participants Who Were Genital Ulcer-free (Complete Response) at Day 169

The percentage of participants who were genital ulcer-free (complete response: free from active genital ulcers)

Time frame:
Day 1 to Day 169
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Genital Ulcer-free (Complete Response) at Day 169
percentage of participantsPlacebo/Apremilast 30 mgApremilast 30mg/Apremilast 30mg
Percentage of Participants Who Were Genital Ulcer-free (Complete Response) at Day 16966.7100
SecondaryPain of Genital Ulcers as Measured by Visual Analog Scale (VAS) at Day 169

A 100-mm VAS pain scale for genital ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.

Time frame:
Day 1 to Day 169

No measurements were reported for this outcome.

SecondaryBehçet's Disease (BD) Current Activity Index Form Score at Day 169

The Behçet's Disease Current Activity Index consists of three component scores, a participant's perception of disease activity, a clinician's overall perception of disease activity and a Behçet's Disease Current Activity Index Score. The score ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening) and a negative change from baseline indicates improvement.

Time frame:
Day 169
Reported as:
Mean · units on a scale
Behçet's Disease (BD) Current Activity Index Form Score at Day 169
units on a scalePlacebo/Apremilast 30 mgApremilast 30mg/Apremilast 30mg
Behçet's Disease (BD) Current Activity Index Form Score at Day 1691.4 ± 1.181.6 ± 1.62
SecondaryNumber of New Manifestations of Behçet's Disease or Flare That Were Not Present at Day 1

A flare was defined as the development of new manifestations of BD or worsening of existing disease, meeting the following criteria: 1. Organ involvement: any major organ involvement (eg, central nervous system, gastrointestinal tract); 2. Oral/genital ulcers: ≥ 100% increase in the number of oral or genital ulcers from Day 1 or a minimum increase of 3 in the number of oral or genital ulcers, whichever is greater; 3. Arthritis: ≥ 50% increase in the number of swollen joints, or a minimum increase of 3 swollen joints, whichever is greater; 4. Skin lesions (non-oral/genital ulcers): ≥ 50% increase in the total score of the Physician's Global Assessment of Skin Lesions, or a minimum increase of 2 in the total score of the Physician's Global Assessment of Skin Lesions, whichever is greater; 5. New onset or worsening of existing Behçet Disease-related inflammatory eye disease requiring initiation of immunosuppressive therapy (uveitis).

Time frame:
Day 1 to Day 169
Reported as:
Number · participants
Number of New Manifestations of Behçet's Disease or Flare That Were Not Present at Day 1
participantsPlacebo/Apremilast 30 mgApremilast 30mg/Apremilast 30mg
Participants who experienced a disease flare1519
Participants with new onset or worsening uveitis12
SecondaryNumber of Oral Ulcers at Day 197

The number of oral ulcers were counted at each visit and at the end of the treatment period (starting point was at baseline).

Time frame:
Day 197
Reported as:
Mean · ulcers/participants
Number of Oral Ulcers at Day 197
ulcers/participantsPlacebo/Apremilast 30 mgApremilast 30 mg /Apremilast 30mg BID (Oral)
Number of Oral Ulcers at Day 1971.6 ± 1.781.7 ± 2.06
SecondaryPain of Oral Ulcers as Measured by VAS (VAS Score) at Day 197

A 100-mm VAS pain scale for oral ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.

Time frame:
Day 197
Reported as:
Mean · units on a scale
Pain of Oral Ulcers as Measured by VAS (VAS Score) at Day 197
units on a scalePlacebo/Apremilast 30 mgApremilast 30 mg /Apremilast 30mg BID (Oral)
Pain of Oral Ulcers as Measured by VAS (VAS Score) at Day 19721.0 ± 22.2627.2 ± 28.71
Other pre-specifiedPercentage of Participants Who Were Genital Ulcer-free (Complete Response)

The percentage of participants who were genital ulcer-free (complete response: free from active genital ulcers)

Time frame:
Day 1 to Day 197
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Genital Ulcer-free (Complete Response)
percentage of participantsPlacebo/Apremilast 30 mgApremilast 30mg/Apremilast 30mg
Percentage of Participants Who Were Genital Ulcer-free (Complete Response)100100
SecondaryPain of Genital Ulcers as Measured by Visual Analog Scale (VAS) at Day 197

A 100-mm VAS pain scale for genital ulcers was completed by the participant at timepoints specified in the protocol. Each 100-mm VAS was presented to the participant on a single sheet of bond paper. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was measured by ruler and recorded. When responding to a VAS item, participants specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.

Time frame:
Day 1 to Day 197

No measurements were reported for this outcome.

SecondaryChange From Baseline in the Disease Activity as Measured by BD Current Activity Form/Index Score on Day 197

The Behçet's Disease Current Activity Index consists of three component scores, a participant's perception of disease activity, a clinician's overall perception of disease activity and a Behçet's Disease Current Activity Index Score. The score ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening) and a negative change from baseline indicates improvement.

Time frame:
Day 1 to Day 197
Reported as:
Mean · units on a scale
Change From Baseline in the Disease Activity as Measured by BD Current Activity Form/Index Score on Day 197
units on a scalePlacebo/Apremilast 30 mgApremilast 30 mg/Apremilast 30mg BID
Change From Baseline in the Disease Activity as Measured by BD Current Activity Form/Index Score on Day 197-0.6 ± 1.28-1.2 ± 1.65
SecondarySummary of Treatment Emergent Adverse Events During the Active Treatment-Extension Phase

A Treatment Emergent Adverse Event (TEAE) is as any AE occurring or worsening on or after the first treatment of any study drug, and within 28 days after the last dose of the last study drug. A treatment related toxicity was considered by the investigator to be not suspected or suspected. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE.

Time frame:
Day 1 to Day 197; maximum exposure was 25.1 weeks
Reported as:
Number · particpants
Summary of Treatment Emergent Adverse Events During the Active Treatment-Extension Phase
particpantsPlacebo BID/Apremilast 30 BID (Oral)Apremilast 30 mg BID/Apremilast 30mg BID (Oral)
Any TEAE3950
Any drug related TEAE2033
Any severe TEAE111
Any serious TEAE15
Any serious drug related TEAE01
TEAE leading to drug interuption01
TEAE leading to drug withdrawal17

Adverse events

Collected over Days 1 to Day 197 visit; maximum exposure to study drug was 25.1 weeks. From Day 1 (first dose) through the end of the follow up period up to 28 days after the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Week 12: Placebo BID—3/56 (5.4%)48/56 (85.7%)
Week 12: Apremilast 30 mg BID—2/55 (3.6%)47/55 (85.5%)
Week 24: Apremilast 30 mg BID—6/100 (6%)82/100 (82%)
Most frequent serious events
Most frequent serious events
EventWeek 12: Placebo BIDWeek 12: Apremilast 30 mg BIDWeek 24: Apremilast 30 mg BID
Behçet's SyndromeImmune system disorders2/560/553/100
DiplegiaNervous system disorders0/561/551/100
Anal FissureGastrointestinal disorders0/561/551/100
HaemorrhoidsGastrointestinal disorders0/561/551/100
PyrexiaGastrointestinal disorders1/560/550/100
InfluenzaInfections and infestations0/560/551/100
Most frequent other events
Showing 10 of 25
Most frequent other events
EventWeek 12: Placebo BIDWeek 12: Apremilast 30 mg BIDWeek 24: Apremilast 30 mg BID
HeadacheNervous system disorders25/5626/5541/100
Behçet's SyndromeImmune system disorders25/5612/5535/100
NauseaGastrointestinal disorders10/5622/5536/100
DiarrhoeaGastrointestinal disorders2/5612/5520/100
VomitingGastrointestinal disorders1/569/5512/100
Abdominal PainGastrointestinal disorders7/568/5511/100
InfluenzaInfections and infestations1/563/5513/100
Pain in ExtremityMusculoskeletal and connective tissue disorders5/566/5513/100
ArthralgiaMusculoskeletal and connective tissue disorders3/563/5511/100
Decreased AppetiteMetabolism and nutrition disorders1/565/555/100

Baseline characteristics

The intent to treat (ITT) population was defined as all randomized participants with at least one oral ulcer evaluation (including the baseline evaluation)

Age, Continuous
Age, Continuous(years)Placebo (Oral) BIDApremilast 30mg (Oral) BIDTotal
Mean34.7 ± 10.9734.3 ± 9.1134.5 ± 10.05
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (Oral) BIDApremilast 30mg (Oral) BIDTotal
Female383977
Male181634
Duration of Behçet's disease
Duration of Behçet's disease(years)Placebo (Oral) BIDApremilast 30mg (Oral) BIDTotal
Mean5.72 ± 6.0844.92 ± 3.9825.33 ± 5.143
08

Study locations

7 sites
  • Mayo Clinic - Rheumatology and Internal Medicine
    Jacksonville, Florida 32224, United States
  • E5, Boston University School of Medicine
    Boston, Massachusetts 02118, United States
  • NYU Hospital for Joint Diseases
    New York, New York 10003, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Eskişehir Osmangazi University
    Eskişehir, 26480, Turkey
  • University of Istanbul
    Istanbul, 34098, Turkey
  • Selçuk University
    Konya, 42080, Turkey
09

References and documents

Publications

  • Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C, Merkel PA, Calamia KT, Liu Z, Pineda L, Stevens RM, Yazici H, Yazici Y. Apremilast for Behcet's syndrome--a phase 2, placebo-controlled study. N Engl J Med. 2015 Apr 16;372(16):1510-8. doi: 10.1056/NEJMoa1408684. PubMed 25875256 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2009 to primary completion in May 2012, 33 months.

Results were first posted in Aug 2014, 2 years 3 months after primary completion. A results delay was requested in May 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2009
First posted
Mar 20, 2009
StartActual
Aug 1, 2009
Primary completionActual
May 1, 2012
CompletionActual
May 1, 2012
Results delay requested
May 29, 2013
Results first posted
Aug 27, 2014
Last update
Jun 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00866359
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 20, 2009
Start date
Aug 1, 2009
Primary completion
May 1, 2012
Completion
May 1, 2012
Results posted
Aug 27, 2014
Last update
Jun 19, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion